Recommendations for Treating Patients With TP53-Mutated AML or MDS
February 6th 2023Melhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.
Watch
Clinical Implications of Recent Advancements in Immunotherapy for NSCLC
February 3rd 2023In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.
Watch
Different Types of Biomarker Testing Methods Used in Patients with NSCLC
January 31st 2023Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.
Watch